Press release

Communiqué de presse

Paris, March 8th, 2012

ARKEMA : FULL YEAR 2011 RESULTS

ADJUSTED NET INCOME UP +33% AT € 574 M
ACCELERATING GROUP TRANSFORMATION

- **Excellent financial performance[1] in globally favorable market conditions**
  - Sales up 21% at 5.9 billion euros
  - EBITDA above 1 billion euros fully in line with guidance
  - EBITDA margin at 17.5%
  - Strong contribution from Asia and solutions for sustainable development
- **Group profile strengthened in specialty chemicals**
  - Acquisition of Total specialty resins and Seppic specialty alcoxylates
  - Acquisition of Hipro and Casda in bio-sourced polyamides in China closed beginning 2012
  - Project to divest Vinyls business to Groupe Klesch[2] (- € 587 m impact on net income)
  - Major investment announced in Thiochemicals in Malaysia
- **Very solid balance sheet with 27% gearing**
- **Proposed dividend at 1.30 euro per share**
- **Upgrade of long-term EBITDA target (2016) at 1,250 million euros[3]**

The Board of Directors of Arkema met on March 7th 2012 to close the consolidated accounts of Arkema for 2011. At the end of the meeting, Thierry Le Hénaff, Chairman and CEO of Arkema stated:

"2011 is a new milestone in Arkema history. Financial performance is excellent and Group transformation has been actively pursued. For the first time, EBITDA exceeds 1 billion euro. This performance represents twice the EBITDA of 2007 in an overall similar macro-environment and reflects the extent of structural improvements achieved by the Group over the past years.

A project to divest the Vinyls business to Groupe Klesch[2] was announced last November. This is a major project for both our Group and all of the employees, men and women of the Vinyls business. Having a strong balance sheet and maintaining the current industrial operations, this new group aims to become a major player in the European PVC industry.

We also announced in 2011 several acquisitions representing close to one billion euros of additional sales and the construction of a Thiochemicals plant in Malaysia, our largest industrial investment so far. These projects reinforce Arkema as one of the top world specialty chemical player."

[1] In application of IFRS 5 rules, income statement and balance sheet items related to Vinyls business subject to a divestment project ongoing at the close of the year are presented in the Group consolidated statements on a separate line.

[2] This project remains subject to the information / consultation of workers councils currently ongoing and to the approval by the relevant antitrust authorities.

[3] In normalized environment

2011 PERFORMANCE

(In millions of euros)	2011	2010	Variation
Sales	5,900	4,869	+21.2%
EBITDA	**1,034**	**809**	**+28%**
EBITDA margin	*17.5%*	*16.6%*	
Industrial Chemicals	*18.6%*	*18.0%*	
Performance Products	*17.4%*	*15.5%*	
Recurring operating income	762	562	+36%
Non-recurring items	(45)	(9)	-
Adjusted net income	**574**	**431**	**+33%**
Net income of discontinued operations	(587)	(78)	-
Net income– Group share	(19)	347	-
Diluted adjusted net income per share (€)	9.21	7.05	+31%

As a divestment project[4] concerning Vinyls business was ongoing at the close of the year, the contribution of this business has been presented in accordance with IFRS 5 rules and terms. 2010 and 2011 income statement items and 2011 balance sheet items of this business have been presented on a separate line in the income statement and balance sheet. However, cash flow statement includes flows related to this Vinyls business.

Sales of continuing operations in 2011 stood at € **5.9** billion, 21% up over 2010. In a context of high raw material and energy costs, Arkema continued to successfully implement its sales price increase policy across all businesses (+14%). The +9% scope of business effect mostly reflects the integration of specialty resins bought from Total on 1st July 2011, which achieved €408 million sales in the 2nd half of the year. Volumes were stable compared to last year. They rose in Performance Products, in particular thanks to the start-ups in Asia and the development of solutions for sustainable development. They recorded a small decrease in Industrial Chemicals due to destocking at year-end.

EBITDA for the first time exceeded the symbolic €1 billion threshold in globally favorable market conditions. It reached € **1,034** million and € 1,010 million including Vinyl Products (€ 790 million in 2010). Market conditions in 2011 were globally favorable with an excellent start of the year in the first half and with destocking in various industrial supply chains at year-end. All Industrial Chemicals and Performance Products business lines contributed to this excellent performance, sustained by the start-up of Kynar® PVDF in Asia, developments in specialty polymers, the acquisition of Total's resins, and a better product mix in particular in Performance Products.

At 17.5%, the **EBITDA margin** grew further compared to 2010 (16.6%) reflecting the quality of Arkema's specialties portfolio.

[4] This project remains subject to the information / consultation of workers councils currently ongoing and to the approval by the relevant antitrust authorities.

Operating income stood at € 717 million against € 553 million in 2010. This includes € 272 million **depreciation and amortization** and - € 45 million **other income and expenses** mainly related to the acquisition of Total specialty resins.

Financial result totalled - € 37 million compared to - € 25 million in 2010. This includes in particular the cost of the € 500 million bond underwritten in October 2010 bearing annual interest of 4% a year.

Income taxes amounted to € 125 million in 2011 (€ 115 million in 2010) representing 16% of the recurring operating income. This low rate results notably from the use of tax loss carry-forwards and the recognition of deferred tax assets for € 22 million mostly in France.

Net income from continuing operations achieved a record level at € 572 million. It represented € 9.21 per share and 9.7% of sales.

Net result of discontinued operations stood at - € 587 million (see details in section "Vinyls business").

Consequently, **net income (Group share)** stood at - € 19 million.

Taking into account the progress achieved by the Group, its confidence in its outlook and according to its distribution policy, the Board of Directors has decided to propose to the next shareholders Annual General Meeting due on May 23rd 2012 the payment of a dividend of € 1.30 per share, an increase of 30% compared to 2011.

2011 SEGMENT PERFORMANCE

Industrial Chemicals: STRONG GROWTH AND HIGH PROFITABILITY

Industrial Chemicals sales grew further reaching € 3,928 million, 24% up on 2010. They include a net contribution of € 408 million from Total specialty resins integrated on 1st July 2011. Prices increased significantly across all product lines in order to offset higher raw material costs. Volumes recorded a slight decline. Following an excellent start to the year, they reflected the return to the traditional 2nd half seasonality in refrigeration and coatings and year-end destocking at customers.

EBITDA reached its highest historical level at € 732 million. All of the segment's businesses made a significant contribution to this result. Fluorogases benefited from favorable market conditions in first half and from the excellent performance of HFC-125 in Asia; Acrylics unit margins were on average high on an overall tight supply and demand balance (mid-cycle assumed for 2012); Thiochemicals results were sustained by worldwide animal feed and oil and gas end-markets, while PMMA benefited from an improved cost structure in Europe.

Several growth projects started or were announced in the course of the year. On Changshu site (China), the Coatex rheology additives unit started in August. A 30% capacity increase for HFC-125 fluorogas and the construction of a new refrigerant blending unit were announced with a start-up scheduled in 2nd half 2012. Finally in Malaysia, Arkema announced a major project for the construction of a thiochemicals platform and a methionine plant in partnership with the Korean company CJ CheilJedang with a start-up scheduled late 2013.

EBITDA margin reached 18.6% (against 18.0% in 2010).

Performance Products: SUCCESSFUL TURNAROUND DRIVEN BY INNOVATION AND ASIA

Performance Products sales amounted to € 1,952 million in 2011, 16% up over 2010. EBITDA rose by 30% to € 339 million from € 260 million in 2010. This increase largely reflects the progress made by Technical Polymers with the rapid ramp-up of the Kynar® PVDF plant started in China in March, and the growth in new applications in areas related to sustainable development. Volumes increased by 4% compared to 2010. Price effect was also highly positive, offsetting high raw material costs and reflecting the repositioning of the portfolio on higher added value products.

Arkema announced several growth projects, which will further strengthen the segment portfolio in 2012:

- with the acquisition of the alcoxylates from Seppic, closed on December 31st, 2011, Arkema expands the specialty products range of its subsidiary Ceca and supports the growth of new rheology additives ranges of Coatex. Sales for this business amounted to € 53 million in 2011;
- the acquisition of Chinese companies Hipro Polymers and Casda Biomaterials, closed on February 1st 2012, allows Arkema to complement its bio-sourced specialty polyamide range (polyamide 10, 11 and 12), to strengthen its presence in Asia and to increase its position in green chemistry. Combined sales for these two companies were around $ 230 million in 2011;
- PVDF Kynar® production capacity in Changshu (China) will be increased by 50% mid-2012.

Vinyls activities

In November 2011, the Group announced a project to divest its Vinyl Products business segment to the Klesch group. This project remains subject to the information/consultation process involving the workers councils currently in progress and to the approval by relevant antitrust authorities. Three Extraordinary Central Committees took place since the project was announced. Closing of the operation is expected mid-2012.

In consolidated financial statements, the project resulted in € 505 million non-recurring expenses related primarily to the € 264 million write-offs of tangible and intangible assets, to a € 151 million provision mainly corresponding to contractual commitments on working capital, and to the negative impact on the Group net debt related to the cash to be transferred (€ 96.5 million).

Full year EBITDA stood at - € 24 million in a challenging European construction market with significant destocking by customers at year-end. 4th quarter results were also impacted by the strike at the LyondellBasell refinery in Berre (France), following the announcement of the refinery shutdown project end of September 2011, and by the strike at Arkema's Vinyls sites following the announcement of the divestment project at the end of the year.

Caustic soda and PVC prices increased, albeit without fully offsetting the rise in ethylene and energy costs.

CASH FLOW AND NET DEBT AT 31 DECEMBER 2011

In 2011, Arkema continuing operations generated a **free cash flow**[5] of € 377 million compared to € 320 million in 2010. This strong cash generation reflects high EBITDA and the strict control of working capital which, at constant scope of business, represents 13.8% of sales despite a significant sales increase. It also includes higher recurring capital expenditures representing € 311 million (€ 243 million in 2010) reflecting the Group increased manufacturing presence in Asia.

Net debt amounts to € 603 million at 31 December 2011 compared to € 94 million end 2010. Gearing remains moderate at 27% representing 0.6 times 2011 EBITDA. Net debt includes the impact of acquisitions and divestments totalling € 568 million and corresponding mainly to the acquisition of both Total specialty resins and Seppic alcoxylates and the investment in a fluorspar mine in Canada, the payment of a € 1 dividend per share totalling € 61 million and € 88 million related to the project to divest Vinyl business. However, it does not include the impact of the acquisitions of Hipro Polymers and Casda Biomaterials closed on 1st February, 2012 on the basis of an enterprise value of $ 365 million.

In July 2011, Arkema set up a new € 700 million syndicated credit line with a July 2016 due date. At the same time, the existing syndicated credit line, with a March 2013 due date, was reduced to € 300 million.

[5] Cash flow including non-reccuring items and excluding impact from M&A

4TH QUARTER 2011

(In millions of euros)	**4Q'11**	**4Q'10**	**Variation**
Sales	**1,400**	**1,197**	**+17.0%**
EBITDA	**158**	**181**	**-13%**
EBITDA margin	*11.3%*	*15.1%*	
Industrial Chemicals	*10.6%*	*17.4%*	
Performance Products	*14.0%*	*9.7%*	
Recurring operating income	76	119	-36%
Non-recurring items	(11)	(8)	-
Net income of continuing operations	**76**	**92**	**-17%**
Net income of discontinued operations	(539)	(33)	-
Net income– Group share	(463)	58	-

While end of 2010 was atypical with restocking by our customers, the 4th quarter 2011 was marked as expected by the return to a more pronounced seasonality. This is the second best performance achieved by Arkema in a 4th quarter.

With a 14% EBITDA margin, Performance Products improved strongly year-on-year confirming the successful repositioning on higher value added and fast-growing product lines.

Industrial Chemicals performance reflects the return to the usual year-end seasonality (refrigeration and coatings) and significant destocking by customers. The gradual volume recovery beginning of 2012 suggests that this destocking was only temporary.

In this context, Arkema achieved a solid performance. Sales of continuing operations of the 4th quarter amount to € 1.4 billion up 17% compared to 2010 and stable at constant foreign exchange rate and scope of business. EBITDA of continuing operations amounts to € 158 million and EBITDA margin at 11.3%.

POST BALANCE SHEET EVENTS

To give employees the opportunity to further benefit from the Group development, the Board of Directors held on March 7th, 2012 has decided to proceed with a share capital increase reserved for employees. The subscription price has been set at € 54.51.

OUTLOOK

2012 should be another year of significant change for Arkema with the integration of Seppic alcoxylates and of Chinese companies Hipro and Casda, the start-up of new units or capacity expansions in Asia and the beginning of the construction of the Thiochemicals plant in Malaysia. The information / consultation process of workers councils on the project to divest Vinyls business to group Klesch will continue and the closing is expected mid 2012.

From a geographical standpoint, growth in Asia should remain well oriented notably in China. Demand improvements are perceivable in the United States and Europe should remain challenging especially in construction. Raw materials are expected to remain volatile at high levels.

While remaining cautious about 2012 macro environment, Arkema is confident in its strengths and will continue to combine strict management of the company with targeted growth.

Since the beginning of the year, volumes are progressing compared to end 2011. The 1st quarter 2012 performance should show a real improvement compared to the 4th quarter 2011 while remaining below a very high 1st quarter 2011. This recovery is expected to continue during the 2nd quarter.

Taking into account the 2011 performance and the portfolio repositioning achieved since spin-off, Arkema upgrades its long-term targets and aims to achieve sales of € 8 billion and an EBITDA of € 1,250 million in 5 years time (2016) while maintaining its gearing at around 40%. This growth would come half from organic growth and half from bolt-on acquisitions. These targets have been defined in normalized environment.

2011 results and outlook are detailed in the presentation "Full year 2011 results" available on the website: www.finance.arkema.com.

The accounts have been audited, and an unqualified certification report is being issued by the Company's auditors.

FINANCIAL CALENDAR

10 May 2012	1st quarter 2012 results
23 May 2012	Shareholders Annual General Meeting
18 September 2012	Arkema Investor Day

*A global chemical company and France's leading chemicals producer, **Arkema** is building the future of the chemical industry every day. Deploying a responsible, innovation-based approach, we produce state-of-the-art specialty chemicals that provide customers with practical solutions to such challenges as climate change, access to drinking water, the future of energy, fossil fuel preservation and the need for lighter materials. With operations in more than 40 countries, 15,700 employees and 9 research centers, Arkema generates annual revenue of €5.9 billion, and holds leadership positions in all its markets with a portfolio of internationally recognized brands. **The world is our inspiration**.*

INVESTOR RELATIONS:

Sophie Fouillat	Tel. : +33 1 49 00 86 37	E-mail : sophie.fouillat@arkema.com
Jérôme Raphanaud	Tel. : +33 1 49 00 72 07	E-mail : jerome.raphanaud@arkema.com

PRESS RELATIONS:

Gilles Galinier	Tél. : +33 1 49 00 70 07	E-mail : gilles.galinier@arkema.com
Sybille Chaix	Tél. : +33 1 49 00 70 30	E-mail : sybille.chaix@arkema.com

Balance sheet, income statement, cash flow statement, statement of changes in shareholders' equity and information by business segment included in this press release are extracted from the consolidated financial statements at December 31st, 2011 closed by the Board of Directors of Arkema S.A. on March 7th, 2012. The consolidated financial statements at December 31st, 2011 were prepared in accordance with international accounting standards as published by IASB (International Accounting Standards Board) at December 31st, 2011 as well as with the international accounting standards as endorsed by the European Union at December 31st, 2011.

Financial information related to 2010 and 2011 is extracted from the consolidated financial statements of Arkema reprocessed, where necessary, to include the impact of discontinued activities. Quarterly financial information is not audited. Business segment information is presented in accordance with Arkema's internal reporting system used by the management.

ARKEMA Financial Statements

Consolidated financial statements - At the end of December 2011

CONSOLIDATED INCOME STATEMENT

(In millions of euros)	4th quarter 2011 (audited)	End of december 2011 (audited)	4th Quarter 2010 (audited)	End of December 2010 (audited)
Sales	**1,400**	**5,900**	**1,197**	**4,869**
	-	-		
Operating expenses	(1,188)	(4,632)	(960)	(3,844)
Research and development expenses	(35)	(132)	(30)	(123)
Selling and administrative expenses	(101)	(374)	(88)	(340)
Recurring operating income	**76**	**762**	**119**	**562**
Other income and expenses	(11)	(45)	(8)	(9)
Operating income	**65**	**717**	**111**	**553**
Equity in income of affiliates	2	17	4	15
Financial result	(11)	(37)	(9)	(25)
Income taxes	20	(125)	(14)	(115)
Net income of continuing operations	**76**	**572**	**92**	**428**
Net income of discontinued operations	**(539)**	**(587)**	**(33)**	**(78)**
Net income	**(463)**	**(15)**	**59**	**350**
Of which non-controlling interests	-	4	1	3
Net income - Group share	**(463)**	**(19)**	**58**	**347**
Of which continuing operations	**76**	**568**	**91**	**425**
Of which discontinued operations	**(539)**	**(587)**	**(33)**	**(78)**
Earnings per share (amount in euros)	*(7.52)*	*(0.31)*	*0.95*	*5.69*
Earnings per share of continuing operations (amount in euros)	*1.24*	*9.22*	*2.22*	*6.96*
Diluted earnings per share (amount in euros)	*(7.52)*	*(0.31)*	*0.93*	*5.67*
Diluted earnings per share of continuing operations (amount in euros)	*1.22*	*9.12*	*2.21*	*6.95*
Depreciation and amortization	(82)	(272)	(62)	(247)
EBITDA	**158**	**1,034**	**181**	**809**
Adjusted net income	**26**	**500**	**76**	**362**
Adjusted net income of continuing operations	**55**	**574**	**102**	**431**
Adjusted net income of discontinued operations	**(29)**	**(74)**	**(26)**	**(69)**
Adjusted net income per share of continuing operations (amount in euros)	*0.89*	*9.31*	*2.37*	*7.06*
Diluted adjusted net income per share of continuing operations (amount in euros)	*0.88*	*9.21*	*2.36*	*7.05*

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

In millions of euros	4th quarter 2011 *(audited)*	End of december 2011 *(audited)*	4th Quarter 2010 *(audited)*	End of December 2010 *(audited)*
Net income	**(463)**	**(15)**	**59**	**350**
Hedging adjustments	7	3	3	3
Deffered taxes on hedging adjustments	-	1	(1)	(1)
Actuarial gains and losses	(45)	(28)	23	(19)
Deffered taxes on actuarial gains and losses	16	11	(5)	3
Other items	2	2	(3)	(1)
Deffered taxes on other items	-	-	-	-
Change in translation adjustments	55	55	23	121
Other comprehensive income of continuing operations	**35**	**44**	**40**	**106**
Other comprehensive income of discontinued operations		**1**	**1**	**1**
Total income and expenses recognized directly in equity	**35**	**45**	**41**	**107**
Comprehensive income	**(428)**	**30**	**100**	**457**
Of which: non-controlling interest	2	6	2	5
Comprehensive income - Group share	**(430)**	**24**	**98**	**452**

CONSOLIDATED BALANCE SHEET

(In millions of euros)	31 December 2011 (audited)	31 December 2010 (audited)
ASSETS		
Intangible assets, net	777	494
Property, plant and equipment, net	1,706	1,703
Equity affiliates : investments and loans	66	55
Other investments	35	38
Deferred tax assets	66	29
Other non-current assets	109	89
TOTAL NON-CURRENT ASSETS	**2,759**	**2,408**
Inventories	945	864
Accounts receivable	834	875
Other receivables and prepaid expenses	117	120
Income taxes recoverable	36	20
Other current financial assets	9	4
Cash and cash equivalents	252	527
TOTAL CURRENT ASSETS	**2,193**	**2,410**
Assets held for sale	380	-
TOTAL ASSETS	**5,332**	**4,818**
LIABILITIES AND SHAREHOLDERS' EQUITY		
Share capital	619	615
Paid-in surplus and retained earnings	1,484	1,567
Treasury shares	(10)	(6)
Translation adjustments	97	43
SHAREHOLDERS' EQUITY - GROUP SHARE	**2,190**	**2,219**
Non-controlling interests	27	21
TOTAL SHAREHOLDERS' EQUITY	**2,217**	**2,240**
Deferred tax liabilities	35	52
Provisions and other non-current liabilities	791	807
Non-current debt	583	587
TOTAL NON-CURRENT LIABILITIES	**1,409**	**1,446**
Accounts payable	665	779
Other creditors and accrued liabilities	265	279
Income taxes payable	39	37
Other current financial liabilities	12	3
Current debt	272	34
TOTAL CURRENT LIABILITIES	**1,253**	**1,132**
Liabilities associated with assets held for sale	453	-
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	**5,332**	**4,818**

CONSOLIDATED CASH FLOW STATEMENT

(In millions of euros)	End of December 2011 (audited)	End of December 2010 (audited)
Cash flow - operating activities		
Net income	(15)	350
Depreciation, amortization and impairment of assets	592	276
Provisions, valuation allowances and deferred taxes	88	(23)
(Gains)/losses on sales of assets	(37)	(11)
Undistributed affiliate equity earnings	(8)	(7)
Change in working capital	(85)	(78)
Other changes	8	4
Cash flow from operating activities	**543**	**511**
Of which cash flow from operating activities of discontinued operations	**(153)**	**(8)**
Cash flow - investing activities		
Intangible assets and property, plant, and equipment additions	(424)	(315)
Change in fixed asset payables	24	36
Acquisitions of subsidiaries, net of cash acquired	(580)	(18)
Increase in long-term loans	(32)	(42)
Total expenditures	**(1,012)**	**(339)**
Proceeds from sale of intangible assets and property, plant and equipment	13	17
Change in fixed asset receivables	-	(3)
Proceeds from sale of subsidiaries, net of cash sold	-	-
Proceeds from sale of unconsolidated investments	45	3
Repayment of long-term loans	12	41
Total divestitures	**70**	**58**
Cash flow from investing activities	**(942)**	**(281)**
Of which cash flow from investing activities from discontinued operations	**(55)**	**(32)**
Cash flow - financing activities		
Issuance (repayment) of shares and other equity	10	23
Purchase of treasury shares	(10)	(7)
Dividends paid to parent company shareholders	(61)	(37)
Dividends paid to minority shareholders	0	(1)
Increase/ decrease in long-term debt	15	500
Increase/ decrease in short-term borrowings and bank overdrafts	177	(317)
Cash flow from financing activities	**131**	**161**
Net increase/(decrease) in cash and cash equivalents	(268)	391
Effect of exchange rates and changes in scope	(5)	47
Cash and cash equivalents at beginning of period	527	89
Cash and cash equivalents at end of period	**254**	**527**
Of which cash and cash equivalents of discontinued operations	**2**	**1**

CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY

(audited)

(In millions of euros)	Shares issued		Paid-in surplus	Retained earnings	Translation adjustments	Treasury shares		Shareholders' equity - Group share	Non-controlling interests	Shareholders' equity
	Number	Amount				Number	Amount			
At January 1, 2011	**61,493,794**	**615**	**1,011**	**556**	**43**	**(136,280)**	**(6)**	**2,219**	**21**	**2,240**
Cash dividend				(61)				(61)		(61)
Issuance of share capital	370,783	4	10	-	-	-	-	14	-	14
Purchase of treasury shares	-	-	-	-	-	(210,000)	(10)	(10)	-	(10)
Cancellation of purchased treasury shares	-	-	-	-	-		-	-	-	-
Grants of treasury shares to employees	-	-	-	(6)	-	132,200	6	-	-	-
Sale of treasury shares	-	-	-	-	-	-	-	-	-	-
Share-based payments	-	-	-	7	-	-	-	7	-	7
Other	-	-	-	(3)	-	-	-	(3)	-	(3)
Transactions with shareholders	**370,783**	**4**	**10**	**(63)**	**-**	**(77,800)**	**(4)**	**(53)**	**-**	**(53)**
Net income	-	-	-	(19)	-	-	-	(19)	4	(15)
Total income and expense recognized directly through equity	-	-	-	(11)	54	-	-	43	2	45
Comprehensive income	**-**	**-**	**-**	**(30)**	**54**	**-**	**-**	**24**	**6**	**30**
At December 31, 2011	**61,864,577**	**619**	**1,021**	**463**	**97**	**(214,080)**	**(10)**	**2,190**	**27**	**2,217**

INFORMATION BY BUSINESS SEGMENT

(audited)

(In millions of euros)	4th Quarter 2011			
	Industrial Chemicals	**Performance Products**	**Corporate**	**Total**
Non-Group sales	938	457	5	**1,400**
Inter segment sales	34	3		
Total sales	**972**	**460**	**5**	
Recurring operating income	**45**	**35**	**(4)**	**76**
Other income and expenses	**(37)**	**33**	**(7)**	**(11)**
Operating income	**8**	**68**	**(11)**	**65**
Equity in income of affiliates	-	-	2	**2**
Details of certain significant non-cash expenses by segment :				
Depreciation and amortization	(54)	(29)	1	**(82)**
Asset impairment charges	(14)	-	-	**(14)**
Provisions	(11)	1	6	**(4)**
EBITDA	**99**	**64**	**(5)**	**158**
Intangible assets and property, plant and equipment additions	**124**	**36**	**6**	**166**
Of which additions of an exceptional nature	35	-	-	35

(In millions of euros)	4th Quarter 2010			
	Industrial Chemicals	**Performance Products**	**Corporate**	**Total**
Non-Group sales	803	390	4	**1,197**
Inter segment sales	32	4		
Total sales	**835**	**394**	**4**	
Recurring operating income	**100**	**14**	**5**	**119**
Other income and expenses	(16)	19	(11)	(8)
Operating income	**84**	**33**	**(6)**	**111**
Equity in income of affiliates	-	-	4	4
Details of certain significant non-cash expenses by segment :				
Depreciation and amortization	(40)	(24)	2	(62)
Asset impairment charges	11	4	(1)	14
Provisions	(29)	13	(2)	(18)
EBITDA	**140**	**38**	**3**	**181**
Intangible assets and property, plant and equipment additions	61	41	1	103
Of which additions of an exceptional nature	8	-	-	8

INFORMATION BY BUSINESS SEGMENT

(audited)

(In millions of euros)	End of December 2011			
	Industrial Chemicals	**Performance Products**	**Corporate**	**Total**
Non-Group sales	3,928	1,952	20	**5,900**
Inter segment sales	154	17	-	
Total sales	**4,082**	**1,969**	**20**	
Recurring operating income	**560**	**240**	**(38)**	**762**
Other income and expenses	**(80)**	**33**	**2**	**(45)**
Operating income	**480**	**273**	**(36)**	**717**
Equity in income of affiliates		1	16	**17**
Details of certain significant non-cash expenses by segment :				
Depreciation and amortization	(172)	(99)	(1)	**(272)**
Asset impairment charges	(14)	-	-	**(14)**
Provisions	11	-	17	**28**
EBITDA	**732**	**339**	**(37)**	**1,034**
Intangible assets and property, plant and equipment additions	**246**	**100**	**19**	**365**
Of which additions of an exceptional nature	54	-	-	**54**

(In millions of euros)	End of December 2010			
	Industrial Chemicals	**Performance Products**	**Corporate**	**Total**
Non-Group sales	3,171	1,680	18	**4,869**
Inter segment sales	140	16		
Total sales	**3,311**	**1,696**	**18**	
Recurring operating income	**417**	**167**	**(22)**	**562**
Other income and expenses	(21)	18	(6)	(9)
Operating income	**396**	**185**	**(28)**	**553**
Equity in income of affiliates		1	14	15
Details of certain significant non-cash expenses by segment :				
Depreciation and amortization	(154)	(93)	-	(247)
Asset impairment charges	9	4	(1)	12
Provisions	6	12	18	36
EBITDA	**571**	**260**	**(22)**	**809**
Intangible assets and property, plant and equipment additions	151	109	5	265
Of which additions of an exceptional nature	19	3	-	22